Krótki przegląd wybranych doustnych leków przeciwcukrzycowych

• Authors: Grzegorz Liczner , Przemysław Sądel , Aleksandra Błażyca , Patrycja Ochapska , Michał Wiciński

Title variants

EN

Short overview of oral antidiabetic drugs

Abstracts

EN

The recently observed increase in the incidence of type 2 diabetes and the high percentage of deaths due to its complications, including diseases of the cardiovascular system, is a significant public health problem today. Type 2 diabetes and cardiovascular disease are the leading causes of hospitalisation in highly developed countries. Prevention of metabolic and vascular complications of type 2 diabetes is a priority action according to the recommendations of modern diabetology. Until recently, outpatient diabetes treatment focused solely on metformin, acarbose, sulfonylureas or thiazolidinediones. The appearance on the market of new oral hypoglycemic drugs made it possible to avoid insulin therapy or postpone the stage at which insulin becomes necessary for the control of diabetes. Some of these drugs significantly reduce the risk of death from cardiovascular causes as well as the frequency of hospitalization due to heart failure with a reduced ejection fraction in both people diagnosed with type 2 diabetes and without concomitant diabetes. The drug that permanently connected diabetes and cardiology is empagliflozin – a competitive inhibitor of the sodium-glucose co-transporter 2.

Keywords

EN

type 2 diabetes; heart failure with reduced ejection fraction; oral antidiabetic drugs; glycosuria; sodium-glucose co-transporter 2 (SGLT2) inhibitors

PL

cukrzyca typu 2; niewydolność serca z obniżoną frakcją wyrzutową; doustne leki przeciw- cukrzycowe; inhibitory kotransportera sodowo-glukozowego 2 (SGLT-2); glukozuria

• Publisher: Wydawnictwo Naukowe Medyk sp. z o.o.
• Journal: Gabinet Prywatny
• Year: 2022
• Volume: 29 (282)
• Issue: 03
• Pages: 15-19

Dates

published

2022

Contributors

author

Grzegorz Liczner

• https://orcid.org/0000000335053295

author

Przemysław Sądel

author

Aleksandra Błażyca

author

Patrycja Ochapska

author

Michał Wiciński

References

• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 Suppl 1:81-90.
• Aretaeus the Cappadocian. Eugene J. Leopold, M.D. Ann Med Hist. 1930;2(4): 424-435.
• MacCracken J, Hoel D. From ants to analogues: Puzzles and promises in diabetes management. Postgrad Med. 1997;101:138-140,143- 145,149-150.
• Frank LL. Diabetes mellitus in the texts of old Hindu medicine (Charaka, Susruta, Vagbhata) Am J Gastroenterol. 1957;27:76-95.
• Dobson M. Experiments and observations on the urine in diabetes. Med Obs Inq. 1776; 5: 298-316.
• Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus: preliminary report. CMAJ. 1922; 12: 141-146.
• Insulin: A 100-Year-Old Discovery With a Fascinating History. William Rostène, Pierre De Meyts; Endocr Rev. 2021;28; 42(5): 503-527.
• Znaczenie pochodnych sulfonylomocznika w terapii cukrzycy typu 2. Czy wszystkie leki z tej grupy w jednakowym stopniu wpływają na ryzyko zgonu z przyczyn ogólnych oraz ryzyko sercowo-naczyniowe? Władysław Grzeszczak. Diabetologia Praktyczna 2011, tom 12, 3: 79-89.
• Meinert C.L., Knatterud G.L., Prout T.E., Klimt C.R. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19 (supl.): 789-830.
• Klepizig H., Kober G., Matter C. i wsp. Sulfonylureas and ischaemic preconditioning: a double-blind, placebo-controlled evaluation of glimepidyde and glibenclamide and glibenclamide. Eur. Heart J. 1999; 20: 439-446.
• Pioglitazon w terapii cukrzycy typu 2. Katarzyna Nabrdalik, Edyta Cichocka, Joanna Żywiec, Artur Chodkowski, Janusz Gumprecht. Diabetologia Kliniczna 2014, tom 3, 4, 176-180.
• Suzuki S., Arnold L.L., Pennington K.L. i wsp. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol. Sci. 2010; 113: 349-357.
• Erdmann E., Dormandy J.A., Charbonnel B., Massi-Benedetti M., Moules I.K., Skene A.M. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J. Am. Coll. Cardiol. 2007; 49: 1772-1780.
• Sieradzki J. Cukrzyca. Via Medica, Gdańsk 2006.
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
• Metformina - nowe wskazania refundacyjne. Krzysztof Strojek, Marta Wróbel, Aleksandra Szymborska-Kajanek, Dominika Rokicka. Diabetologia Kliniczna 2013, tom 2, 4, 120-124.
• Sieradzki J. Leki blokujące alfa-glukozydazę. W: Grzeszczak W. (red.) Farmakoterapia w cukrzycy. Via Medica, Gdańsk 2010; 92-104.
• Chiasson J.L., Josse R.G., Gomis R. i wsp. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002; 359: 2072-2077.
• Chiasson J.L., Josse R.G., Gomis R. i wsp. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA 2003; 290: 486-494.
• Goke B., Herrmann C., Goke R. i wsp. Intestinal effects of alfa-glucosidase inhibitors: absorption of nutrients and enterohormonal changes. Eur. J. Clin. Invest. 1994; 24 (supl. 3): 25-30.
• Seifarth C., Bergmann J., Holst J.J. i wsp. Prolonged and enhanced secretion of glucagon-like peptide (7-36 amide) after oral inhibition of glucose absorption (acarbose) in type 2 diabetic patients. Diabetic Med. 1998; 15: 485-491.
• Inhibitory kotransportera glukozowo--sodowego 2 (SGLT2): nowa grupa doustnych leków przeciwcukrzycowych. Błażej Przybysławski , Piotr Karbowiak, Jacek Rzeszotarski , Lech Walasek. Diabetologia Kliniczna 2013, tom 2, 5, 191-197.
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi, EMPA-REG OUTCOME Investigators. N Engl J Med 2015; 26; 373(22): 2117-2128

Identifiers

DOI

10.57591/GP.202203.02

Biblioteka Nauki

2080186